The Federal Food & Drug Administration notified healthcare professionals of a recall of Methotrexate Injection, 50mg/2mL and 250mg/10mL vials, due to small glass flakes detected in a limited number of vials in four lots. According to Sandoz and the FDA, potential adverse events after intravenous administration include local damage to blood vessels in the lung, localized swelling, and granuloma formation. Intramuscular administration could result in foreign-body inflammatory response, with local pain, swelling and possible long term granuloma formation. Additionally, neurologic damage could result from intrathecal administration.
Posted by Louisville, Kentucky lawyer Larry Jones. Larry can be reached at larry@jonesward.com or by using his toll-free number 1-888-KYLAW22.
